Literature DB >> 15977317

Introduction: novel therapies in developmental disabilities--hope, reason, and evidence.

Susan L Hyman1, Susan E Levy.   

Abstract

Complementary and alternative medicine (CAM) is used both alongside (complementary) and as a substitute for (alternative) conventional therapies. Although CAM use is reported to be high among children with typical development, reported rates for CAM use to address symptoms of children with developmental disabilities may be higher. Increased use in this population may relate to hope for amelioration of symptoms, concerns regarding side effects of conventional treatments, and a need on the part of families to participate in decision making regarding their child's care. Primary health care providers may find that the child's needs are best served when they maintain a dialogue with families to evaluate the evidence supporting novel therapies. Interventions need to be assessed in an evidence based fashion whether or not they are initially preceived as CAM. This issue of Mental Retardation and Developmental Disabilities Research Reviews contains reviews of CAM used to treat several developmental disabilities as well as some broader discussions related to the determinants of CAM use, current efforts to evaluate novel therapies, and how to consider the possibility of placebo effects. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15977317     DOI: 10.1002/mrdd.20060

Source DB:  PubMed          Journal:  Ment Retard Dev Disabil Res Rev        ISSN: 1080-4013


  10 in total

Review 1.  Complementary and alternative medicine in developmental disabilities.

Authors:  Kelly A Brown; Dilip R Patel
Journal:  Indian J Pediatr       Date:  2005-11       Impact factor: 1.967

2.  Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism.

Authors:  S Jill James; Stepan Melnyk; George Fuchs; Tyra Reid; Stefanie Jernigan; Oleksandra Pavliv; Amanda Hubanks; David W Gaylor
Journal:  Am J Clin Nutr       Date:  2008-12-03       Impact factor: 7.045

Review 3.  Autoimmunity in autism.

Authors:  Amanda M Enstrom; Judy A Van de Water; Paul Ashwood
Journal:  Curr Opin Investig Drugs       Date:  2009-05

4.  Parent disclosure of complementary health approaches used for children with autism spectrum disorder: Barriers and facilitators.

Authors:  Olivia Lindly; Sheryl Thorburn; Karen Heisler; Nuri Reyes; Katharine Zuckerman
Journal:  Complement Ther Med       Date:  2017-09-12       Impact factor: 2.446

5.  Parents' Use of Complementary Health Approaches for Young Children with Autism Spectrum Disorder.

Authors:  Olivia J Lindly; Sheryl Thorburn; Karen Heisler; Nuri M Reyes; Katharine E Zuckerman
Journal:  J Autism Dev Disord       Date:  2018-05

6.  A review of complementary and alternative treatments for autism spectrum disorders.

Authors:  Nicholas Lofthouse; Robert Hendren; Elizabeth Hurt; L Eugene Arnold; Eric Butter
Journal:  Autism Res Treat       Date:  2012-11-28

7.  Effectiveness of methylcobalamin and folinic Acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status.

Authors:  Richard E Frye; Stepan Melnyk; George Fuchs; Tyra Reid; Stefanie Jernigan; Oleksandra Pavliv; Amanda Hubanks; David W Gaylor; Laura Walters; S Jill James
Journal:  Autism Res Treat       Date:  2013-10-12

8.  Concurrent Complementary and Alternative Medicine CAM and Conventional Rehabilitation Therapy in the Management of Children with Developmental Disorders.

Authors:  Soo Yeon Kim; Yong-Il Shin; Sang-Ook Nam; Chang-Hyung Lee; Yong Beom Shin; Hyun-Yoon Ko; Young-Ju Yun
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-12       Impact factor: 2.629

9.  A randomized controlled trial of the computer-based cognitive rehabilitation program for children (CoTras-C) to examine cognitive function and visual perception in children with developmental disabilities.

Authors:  Jin-Hyuck Park; Ji-Hyuk Park
Journal:  J Phys Ther Sci       Date:  2015-12-28

Review 10.  Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

Authors:  Marzena Wyganowska-Świątkowska; Maja Matthews-Kozanecka; Teresa Matthews-Brzozowska; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Int J Mol Sci       Date:  2018-01-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.